These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9345421)

  • 41. Tumour necrosis factor and anti-tumour necrosis factor approach to inflammatory demyelinating diseases of the central nervous system.
    Selmaj KW
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i94-102. PubMed ID: 11053098
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of imatinib mesylate in mouse models of multiple sclerosis and in vitro determinants.
    Azizi G; Haidari MR; Khorramizadeh M; Naddafi F; Sadria R; Javanbakht MH; Sedaghat R; Tofighi Zavareh F; Mirshafiey A
    Iran J Allergy Asthma Immunol; 2014 Jun; 13(3):198-206. PubMed ID: 24659124
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple sclerosis: trapped in deadly glue.
    Platten M; Steinman L
    Nat Med; 2005 Mar; 11(3):252-3. PubMed ID: 15746934
    [No Abstract]   [Full Text] [Related]  

  • 44. The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases.
    Huang Y; Erdmann N; Peng H; Zhao Y; Zheng J
    Cell Mol Immunol; 2005 Apr; 2(2):113-22. PubMed ID: 16191417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours.
    Gallo P; Piccinno MG; Krzalic L; Tavolato B
    J Neuroimmunol; 1989 Jun; 23(1):41-4. PubMed ID: 2723041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intensive suppression of experimental allergic encephalomyelitis (EAE) by serum thymic factor and therapeutic implication for multiple sclerosis.
    Nagai Y; Osanai T; Sakakibara K
    Jpn J Exp Med; 1982 Aug; 52(4):213-9. PubMed ID: 6983610
    [No Abstract]   [Full Text] [Related]  

  • 47. Kynurenines, redox disturbances and neurodegeneration in multiple sclerosis.
    Rajda C; Bergquist J; Vécsei L
    J Neural Transm Suppl; 2007; (72):323-9. PubMed ID: 17982910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histamine and histamine receptors in pathogenesis and treatment of multiple sclerosis.
    Jadidi-Niaragh F; Mirshafiey A
    Neuropharmacology; 2010 Sep; 59(3):180-9. PubMed ID: 20493888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pathological and protective effects of tumor necrosis factor-alpha in multiple sclerosis].
    Smagina IV; Elchaninova SA; Palashchenko AS; Galaktionova LP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):14-20. PubMed ID: 31934984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Multiple sclerosis as an adverse effect of anti-tumor necrosis factor agents: an infrequent but important complication of infliximab in Crohn's disease].
    Mir Subías A; García-López S; Sebastián Torres B; Ollero Domenche L; García Gámez A; Gomollón F
    Gastroenterol Hepatol; 2013 Feb; 36(2):81-5. PubMed ID: 23218770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug discovery: In defence of the animal model.
    Baldarelli RM
    Nature; 2012 May; 485(7398):309. PubMed ID: 22596144
    [No Abstract]   [Full Text] [Related]  

  • 52. Chemokines in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Babcock A; Owens T
    Adv Exp Med Biol; 2003; 520():120-32. PubMed ID: 12613576
    [No Abstract]   [Full Text] [Related]  

  • 53. Suppression of experimental autoimmune encephalomyelitis by sulfasalazine.
    Prosiegel M; Neu I; Ruhenstroth-Bauer G; Hoffmann G; Vogl S; Mehlber L; Wildfeuer A
    N Engl J Med; 1989 Aug; 321(8):545-6. PubMed ID: 2569670
    [No Abstract]   [Full Text] [Related]  

  • 54. Failure of sulfasalazine to influence experimental autoimmune encephalomyelitis.
    Uitdehaag BM; Polman CH; de Groot CJ; Huitinga I; Dijkstra CD
    Acta Neurol Scand; 1991 Aug; 84(2):173-4. PubMed ID: 1683088
    [No Abstract]   [Full Text] [Related]  

  • 55. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections.
    Arnon R
    Immunol Lett; 1996 Apr; 50(1-2):1-15. PubMed ID: 8793553
    [No Abstract]   [Full Text] [Related]  

  • 56. Misfiring in multiple sclerosis: cerebellar channelopathy, a potential novel target?
    Craner MJ; Fugger L
    Ann Neurol; 2012 Apr; 71(4):437-8. PubMed ID: 22522437
    [No Abstract]   [Full Text] [Related]  

  • 57. Cost of disease-modifying therapies for multiple sclerosis.
    Brown MG
    Neurology; 2015 May; 84(21):e181-5. PubMed ID: 26009567
    [No Abstract]   [Full Text] [Related]  

  • 58. Monitoring multiple sclerosis course and activity with TNF-alpha.
    Chofflon M; Fellay B
    Mult Scler; 1998 Jun; 4(3):188-92. PubMed ID: 9762672
    [No Abstract]   [Full Text] [Related]  

  • 59. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Rittenhouse BE
    Neurology; 2015 Nov; 85(19):1727-8. PubMed ID: 26866071
    [No Abstract]   [Full Text] [Related]  

  • 60. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Tischner JR
    Neurology; 2015 Nov; 85(19):1727. PubMed ID: 26553943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.